1. Home
  2. OXLCO vs REVBW Comparison

OXLCO vs REVBW Comparison

Compare OXLCO & REVBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OXLCO
  • REVBW
  • Stock Information
  • Founded
  • OXLCO N/A
  • REVBW N/A
  • Country
  • OXLCO United States
  • REVBW United States
  • Employees
  • OXLCO N/A
  • REVBW 9
  • Industry
  • OXLCO Investment Managers
  • REVBW Biotechnology: Pharmaceutical Preparations
  • Sector
  • OXLCO Finance
  • REVBW Health Care
  • Exchange
  • OXLCO Nasdaq
  • REVBW Nasdaq
  • Market Cap
  • OXLCO N/A
  • REVBW N/A
  • IPO Year
  • OXLCO N/A
  • REVBW 2020
  • Fundamental
  • Price
  • OXLCO $23.05
  • REVBW $0.02
  • Analyst Decision
  • OXLCO
  • REVBW
  • Analyst Count
  • OXLCO 0
  • REVBW 0
  • Target Price
  • OXLCO N/A
  • REVBW N/A
  • AVG Volume (30 Days)
  • OXLCO N/A
  • REVBW N/A
  • Earning Date
  • OXLCO N/A
  • REVBW N/A
  • Dividend Yield
  • OXLCO N/A
  • REVBW N/A
  • EPS Growth
  • OXLCO N/A
  • REVBW N/A
  • EPS
  • OXLCO N/A
  • REVBW N/A
  • Revenue
  • OXLCO N/A
  • REVBW N/A
  • Revenue This Year
  • OXLCO N/A
  • REVBW N/A
  • Revenue Next Year
  • OXLCO N/A
  • REVBW N/A
  • P/E Ratio
  • OXLCO N/A
  • REVBW N/A
  • Revenue Growth
  • OXLCO N/A
  • REVBW N/A
  • 52 Week Low
  • OXLCO N/A
  • REVBW N/A
  • 52 Week High
  • OXLCO N/A
  • REVBW N/A
  • Technical
  • Relative Strength Index (RSI)
  • OXLCO 59.90
  • REVBW N/A
  • Support Level
  • OXLCO $22.97
  • REVBW N/A
  • Resistance Level
  • OXLCO $23.10
  • REVBW N/A
  • Average True Range (ATR)
  • OXLCO 0.05
  • REVBW 0.00
  • MACD
  • OXLCO 0.01
  • REVBW 0.00
  • Stochastic Oscillator
  • OXLCO 88.09
  • REVBW 0.00

About OXLCO Oxford Lane Capital Corp. Preferred Stock Shares 6.00% Series 2029

Oxford Lane Capital Corp is a non-diversified closed-end management investment company. The fund's investment objective is to maximize its portfolio's risk-adjusted total return over its investment horizon. Its current focus is to seek that return by investing in equity and junior tranches of CLO(collateralized loan obligation) vehicles, which are collateralized by a diverse portfolio of senior loans, and which generally have little to no exposure to real estate loans, mortgage loans or pools of consumer-based debt, such as credit card receivables or auto loans. Its investment plan also includes investing in warehouse facilities, which are financing structures intended to aggregate senior loans that may be used to form the basis of a CLO vehicle.

About REVBW Revelation Biosciences Inc. Warrant

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Share on Social Networks: